跳到正文
FDA 官方药品与生物制品信息·· 16 天前AI 评分42

FDA 健康促进办公室(OHA)发布 2026 年及 2027-2028 年指南议程并征求意见(FDA-2024-N-5427)

Office of Health Advancement (OHA) Guidance Agenda

AI 导读

美国 FDA 健康促进办公室(OHA)公布 2026 年拟发布及 2027-2028 年拟制定的指南文件清单,涉及组合产品、临床试验、儿科产品开发和罕见病等主题,并明确 OCMO 不受清单约束、可不发布全部指南。公众可随时通过 Docket FDA-2024-N-5427 提交意见,OHA 希望于 2026 年 6 月 8 日前收到反馈以便及时调整指南制定计划。

正文 · 原文

The Office of Health Advancement (OHA) is sharing the following lists of guidance documents for public review and input:

  1. Guidance documents we intend to publish in calendar year 2026.
  2. Guidance documents we are developing and intend to publish in calendar years 2027-2028 as resources permit.

These lists include topics that currently have no guidance associated with them, topics for which updated guidance may be helpful, and topics for which OCMO has already issued draft guidances that may be revised or finalized following review of public comments. We currently intend to develop guidance documents on these topics; however, OCMO is neither bound by these lists of topics nor required to issue every guidance document on the lists. Several factors may impact our ability to issue a guidance, including, for example, new priorities, emerging public health issues, or other extenuating circumstances. We may also issue guidance documents on topics that are not included on these lists.

You may submit comments on the guidance topics in these lists at www.regulations.gov at Docket FDA-2024-N-5427.

Although you may submit comments at any time, OCMO appreciates comments on the guidance topics in these lists by June 8, 2026. Comments submitted by this date will allow OCMO to make any necessary adjustments to its guidance development plans in a more timely manner.


Calendar Year 2026 Priorities

OCMO Lead OfficeGuidance TopicCategory
Office of Combination ProductsEssential Drug Delivery Outputs for Devices Intended to Deliver Drugs and Biological ProductsCombination Products
Office of Combination ProductsCurrent Good Manufacturing Practice Requirements for Combination ProductsCombination Products
Office of Combination ProductsLabeling for Infusion Pumps that Deliver Subcutaneous InsulinMedical Products
Office of Public Health Preparedness and ResponseEmergency Use Authorization of Medical Products and Related AuthoritiesMedical Products

Anticipated Guidances—Calendar Years 2027-2028

OCMO Lead OfficeGuidance TopicCategory
Office of Clinical PolicyKey Information and Facilitating Understanding in Informed Consent†Clinical Trials
Office of Clinical PolicyPayment and Reimbursement to Research ParticipantsClinical Trials
Office of Clinical PolicyInstitutional Review Board Waiver or Alteration of Informed Consent for Minimal Risk Research under 21 CFR 50.22†Clinical Trials
Office of Combination ProductsUnique Device Identifier (UDI) Requirements for Combination ProductsCombination Products
Office of Combination ProductsSubmissions for Postapproval Modifications to a Combination ProductCombination Products
Office of Combination ProductsTechnical Considerations for Demonstrating Reliability of Emergency-Use InjectorsCombination Products
Office of Combination ProductsCross-Center Master Files: Where to SubmitMedical Products
Office of Pediatric TherapeuticsEthical Considerations for Clinical Investigations of Medical Products Involving ChildrenPediatric Product Development
Office of Pediatric TherapeuticsResearch Involving Children as Subjects and Not Otherwise Approvable by an Institutional Review Board: Process for Referrals to Food and Drug Administration and Office for Human Research ProtectionsPediatric Product Development
Office of Orphan Products DevelopmentFormatting and Assembling Requests for Orphan Drug DesignationRare Diseases
Office of Orphan Products DevelopmentOverview of the Orphan Drug Designation ProgramRare Diseases

† Note: This guidance is being developed in collaboration with the HHS Office for Human Research Protections.


Additional Resources

来源:FDA 官方药品与生物制品信息 · fda.gov